Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Exp Eye Res. 2010 Jul 1;91(3):425–432. doi: 10.1016/j.exer.2010.06.017

Figure 4. Adenosine A3 receptor agonist MRS 3558 prevents the lethal effect of BzATP.

Figure 4

A) Contralateral eyes were injected with either 250 μM BzATP or 250 μM BzATP + 10 μM A3 receptor agonist MRS3558. Co-injection of MRS3558 significantly increased the number of surviving ganglion cells in the nasal and superior quadrants (* p<0.001, paired t-test, n=48 corresponding regions from 8 adolescent rats).

B) Representative image from peripheral nasal region of eye injected with BzATP.

C) Corresponding region from contralateral eye injected with BzATP + MRS3558. In panels C and D, bar = 50 μm.